3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Conditions
Colorectal Neoplasms
50
Neoplasms
13
Neoplasm Metastasis
12
Gastrointestinal Stromal Tumors
10
Carcinoma, Hepatocellular
7
Glioblastoma
5
Colonic Neoplasms
5
Sarcoma
4
Stomach Neoplasms
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Ovarian Neoplasms
3
Liver Neoplasms
3
Rhabdomyosarcoma
2
Rectal Neoplasms
2
Pancreatic Neoplasms
2
Gallbladder Neoplasms
2
Esophageal Neoplasms
2
Colorectal Cancer Metastatic
2
Cholangiocarcinoma
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Bile Duct Neoplasms
2
Advanced Cancer
2
Wilms Tumor
1
Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer)
1
Thymoma
1
Squamous Cell Carcinoma of Head and Neck
1
Somatostatinoma
1
Solid Tumor
1
Sarcoma, Ewing
1
Interventions
Sunitinib
3
Thymectomy
2
Taxes
2
Prednisone
2
Pemetrexed
2
Paclitaxel
2
Octreotide
2
Imatinib Mesylate
2
Erlotinib Hydrochloride
2
Cisplatin
2
Carboplatin
2
vorolanib
1
regorafenib
1
pembrolizumab
1
olaparib
1
lenvatinib
1
entinostat
1
bosutinib
1
belinostat
1
atezolizumab
1
anetumab ravtansine
1
amrubicin
1
Ramucirumab
1
Radiotherapy
1
Radiosurgery
1
Radiofrequency Ablation
1
Psychiatric Rehabilitation
1
Prednisolone
1
Patient Comfort
1
Palliative Care
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Thymoma
×
regorafenib
×
Clear all
NCT02307500
2022-09-10
RESOUND
Istituto Clinico Humanitas
Phase 2
Completed
82 enrolled